AH8
Acetyl hexapeptide-8
A synthetic hexapeptide, Glu-Glu-Met-Gln-Arg-Arg, acetylated at the N-terminus and amidated at the C-terminus. The sequence is modelled on the N-terminal end of SNAP-25, a protein in the vesicle-fusion complex. It is regulated as a cosmetic ingredient rather than as a drug.
Acetyl hexapeptide-8 has 2 registered human studies on ClinicalTrials.gov, reaching phase 2, covering 22 planned or enrolled participants across the 2 studies that published a figure. No FDA-approved product contains Acetyl hexapeptide-8. 19 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Acetyl hexapeptide-8; the registry search is fuzzy, so every match is re-checked. None of this says whether Acetyl hexapeptide-8 works or is safe.
FDA status
Research only
Human studies
2
Furthest phase
Phase 2
Papers, 10 yr
19
Readership
537
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Phase 1 or 2 only
2
Registered human studies
Phase 2
Furthest phase reached
22
Planned or enrolled participants, across 2 studies that published a figure
None
No FDA-approved product contains it
6 loose registry matches were checked and 2 confirmed — 4 named something else and were discarded. We count a study only when Acetyl hexapeptide-8 is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Acetyl hexapeptide-8 is, and what it has been studied for
Acetyl hexapeptide-8 is tracked here.
Across 2 registered trials, it has been studied in Oily Skin and Focal Dystonia. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by University of California, Davis and National Institute of Neurological Disorders and Stroke (NINDS). A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Acetyl hexapeptide-8 reached Phase 2 across 2 registered trials.
No FDA-approved product contains Acetyl hexapeptide-8. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Acetyl hexapeptide-8?
Papers published each year that name Acetyl hexapeptide-8 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 1 | 0 | Yes |
| 2020 | 2 | 0 | Yes |
| 2021 | 1 | 0 | Yes |
| 2022 | 0 | 0 | Yes |
| 2023 | 1 | 0 | Yes |
| 2024 | 3 | 0 | Yes |
| 2025 | 8 | 0 | Yes |
| 2026 | 4 | 0 | No |
19 papers between 2017 and 2026. A paper counts when “Acetyl hexapeptide-8” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Acetyl hexapeptide-8
19 indexed papers name Acetyl hexapeptide-8 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy
- Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis
- Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics
- Polydioxanone Bioactive Sutures-Acetyl Hexapeptide-8 (Argireline): An Intelligent System for Controlled Release in Facial Harmonization
- Acetyl Hexapeptide-8 as a Topical Alternative to Botulinum Toxin: A Review of the Literature
- Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure
- In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation
- Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8
Collected 2026-08-02from PubMed, phrase-matched on “Acetyl hexapeptide-8” in title and abstract. Run the same search.
About Acetyl hexapeptide-8
A synthetic hexapeptide, Glu-Glu-Met-Gln-Arg-Arg, acetylated at the N-terminus and amidated at the C-terminus. The sequence is modelled on the N-terminal end of SNAP-25, a protein in the vesicle-fusion complex. It is regulated as a cosmetic ingredient rather than as a drug.
- Also known as
- Acetyl hexapeptide-3
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.